Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on offering nets $70.8mm for Aquinox

Executive Summary

Aquinox Pharmaceuticals Inc. (targeted immuno-oncology and inflammation therapies) netted $70.8mm through the public sale of 6.15mm common shares (including the overallotment) at $12.25. Proceeds will support development activities, including work on lead project AQX1125 (Phase II for COPD and bladder pain syndrome/interstitial cystitis), and will also fund pre-commercialization and market assessment activities.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies